Earnings
488 articles in this category (Page 16 of 21)
Microsoft (MSFT) Faces Range-Bound Trading Amid Mixed Analyst Sentiment and Heavy AI CapEx
Microsoft is expected to trade sideways over the next 21 days as strong long-term AI fundamentals clash with near-term margin pressures and recent analyst downgrades.
TSLA 21-Day Outlook: Bearish Sentiment and Fundamental Contradictions Point to Downside Risk
Declining deliveries and a massive 14% gap between gross and net margins signal operational inefficiency, driving a bearish 21-day outlook despite isolated analyst upgrades.
ImmunityBio (IBRX) Faces Consolidation as Overbought Technicals Clash with Global Approval Euphoria
Despite securing global approvals and 700% revenue growth, IBRX is expected to trade sideways as an overbought RSI of 79.90 and severe cash burn cap near-term upside.
ACLX 5-Day Outlook: Extreme Overbought Conditions and Earnings Risk Threaten Recent 78% Surge
Despite 100% bullish news sentiment, Arcellx faces severe pullback risks as its RSI hits 82.85 and shares trade above the average analyst price target ahead of its February 26 earnings.
BillionToOne (BLLN): Medicare Coverage and Upcoming Earnings Setup Potential Rebound
Recent Medicare coverage for Northstar Select and reiterated revenue guidance provide strong catalysts for BLLN ahead of its March 4 earnings, despite weak technical momentum.
ImmunityBio (IBRX) 21-Day Outlook: Increase Expected Amidst Global ANKTIVA Approvals Despite Overbought Technicals
ImmunityBio's massive 700% revenue growth and new international ANKTIVA approvals signal upside potential, though overbought technicals and deep negative margins cap confidence.